Case Report: Dual toxicity of voriconazole in a CYP2C19 poor metabolizer: a case analysis of life-threatening neutropenia and hepatocellular injury
Abstract
Background: Voriconazole, a first-line therapy for invasive aspergillosis, exhibits variable pharmacokinetics due to CYP2C19 polymorphisms. However, severe hematological toxicity, particularly life-threatening neutropenia, remains under-recognized. The concomitant occurrence of dual severe organ toxicities in CYP2C19 poor metabolizers (PMs) poses a significant clinical challenge.
Case: We report a case of a 71-year-old Chinese male with invasive pulmonary aspergillosis. After approximately 40 days of oral voriconazole therapy (400 mg q12h loading dose, then 200 mg q12h maintenance), he sequentially developed grade 4 neutropenia (Absolute Neutrophil Count nadir 0.02 × 109/L) with fever and grade 3 hepatocellular liver injury (Alanine Aminotransferase [ALT] peak 738 U/L; R ratio approximately 65.9). Pharmacogenomic testing performed during hospitalization on 27 March 2025 revealed a CYP2C19 *2/*3 PM genotype. Causality assessments using the Naranjo and RUCAM scales rated both events as probable in relation to voriconazole. Following discontinuation of voriconazole, antifungal therapy was sequentially changed to isavuconazonium sulfate, nebulized amphotericin B liposome, and intravenous amphotericin B cholesteryl sulfate complex, together with granulocyte colony-stimulating factor and hepatoprotective therapy. The patient's neutrophil count and liver function improved, and he was discharged in stable condition with isavuconazonium sulfate capsules 200 mg qd after discharge.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.